Use of Tamoxifen in Systemic Mastocytosis
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 11/16/2018 |
| Start Date: | February 2005 |
| End Date: | October 2020 |
| Contact: | Joseph H Butterfield, MD |
| Email: | butterfield.joseph@mayo.edu |
| Phone: | 507-284-9077 |
Treatment of Systemic Mastocytosis With Tamoxifen
In this study, the investigators will determine the utility of Tamoxifen, a non-cytotoxic
agent, to improve quality of life, biochemical parameters, and bone marrow involvement in
systemic mastocytosis patients having 1) up to 40% bone marrow infiltration by mast cells
and/or 2) mediator-release symptoms which are not controlled by tolerated doses of standard
"non-cytotoxic" medications regardless of the percentage bone marrow involvement by
mastocytosis. The dose of Tamoxifen will be 40 mg/day and the duration of treatment will be
for one year. Patients currently taking interferon alfa, imatinib mesylate, or cladribine
will be excluded until these medications have been stopped.
agent, to improve quality of life, biochemical parameters, and bone marrow involvement in
systemic mastocytosis patients having 1) up to 40% bone marrow infiltration by mast cells
and/or 2) mediator-release symptoms which are not controlled by tolerated doses of standard
"non-cytotoxic" medications regardless of the percentage bone marrow involvement by
mastocytosis. The dose of Tamoxifen will be 40 mg/day and the duration of treatment will be
for one year. Patients currently taking interferon alfa, imatinib mesylate, or cladribine
will be excluded until these medications have been stopped.
Not desired
Inclusion Criteria:
- Systemic Mastocytosis
Exclusion Criteria:
- Current treatment with Imatinib mesylate, cladribine or interferon alpha.
We found this trial at
1
site
Click here to add this to my saved trials
